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Abstract 
Purpose: To demonstrate whether miR-495-3p promote the occurrence of colon cancer and 
development of colon cancer stem cells by inhibiting Wnt inhibitory factor (WIF1). 
Methods: The level of MiRNA and mRNA in cells were tested by real-time polymerase chain reaction 
(RT-PCR). Cell viability was assessed by 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium 
bromide (MTT) assay. Cell spheroid formation was measured by colony assay. Expression protein was 
tested using Western blotting. β-catenin binding ability was detected by chromatin immunoprecipitation 
(ChIP) assay. MiRNA target gene was defined by luciferase assay.  
Results: Compared with normal colon cells and tissue, miR-495-3p is elevated in colon cancer cells 
and tissues, which regulate proliferation, level of stemness factors SOX-9, Bmil, and OCT-4 in HCT-116 
cells, even spheroid formation. Overexpression of miR-495-3p inhibits the expression of WIF1 in HCT-
116 cells and promotes colon tumorigenesis by binding with 3’-UTR. MiR-495-3p inhibitor 
downregulated WIF1-enhanced sphere formation of colon cancer cells.   
Conclusion: These results indicate that miR-495-3p/WIF1 can modulate the development of colon 
cancer and is a potential target for prevention and treatment of cancer.  
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Colorectal cancer is a heavy burden around the 
world that accounts for more than 1 million newly 
diagnosed cases and more than six hundred 
thousand patients die of every year [1]. However, 
its incidence has declined in a number of 
Western countries, mainly because of early 
detection, prevention, and treatment measures 
[2]. Therefore, the underlying etiologies 
impacting colon cancer tumorigenesis has to be 
classified to help in monitoring the progress of 
therapy. At present, molecular targets have been 
investigated in the treatment of many types of 
cancer. MicroRNAs (miRNAs) are proposed to 
be prospective candidates for cancer therapy. 
MiRNAs are small RNAs comprising of of 20-25 
nucleotides, which cannot code for protein but 
regulate expression of gene through reacting 
with mRNAs. By complementary binding to the 
3’-UTR of target mRNAs, miRNAs either 
suppress mRNAs translation or degrade them 
directly [3]. MiR-495 was previously considered 
to be a breast cancer cell promoter that targeted 
the regulation of E-cadherin and REDD1 [4]. This 
miRNA was also observed to be decreased in 
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MLL-rearranged leukemia [5] and in gastric 
cancer cells where it is a suppressor of 
phosphatase of regenerating liver-3 (PRL-3) [6]. 
PRL-3 gene is closely related to gastric cancer 
metastasis, and is proposed to play an initating 
role by facilitating cancer cell migration and 
invasion. MiR-495 was also previously reported 
to shift the metabolic mode in glioma cells 
through targeting Glut1 [7]. Wang observed that 
miR-495 could regulate Bmi-1 to arrest the G1 to 
S phase transition in breast cancer [8]. Very 
recently, miR-495 was found to participate in Wnt 
signaling pathway regulation in cardiomyocyte 
proliferation [9], whose main function is to 
promote cell proliferation and differentiation 
[10,11]. However, little else is known about the 
reverse chain of miR-495, miR-495-3p, the 
implications of its function and expression in 
colon cancer. 
 
It was observed in this study that miR-495-3p is 
elevated in colon cancer cell compared to control 
group both at tissue and cellular levels. MiR-495-
3p promoted colon cancer cell growth and 
tumorigenesis in vitro. We also revealed that Wnt 
inhibitory factor 1 (WIF1) is the direct target of 
miR-495-3p. MiR-495-3p is a potential 
therapeutic target worth further investigation in 




Tissue collection and RNA extraction 
 
The tissue samples used in this study were 
collected from Shenzhen Second People’s 
Hospital colon cancer patients. Trizol standard 
method was adopted to extract the total RNA. 
This study was approved by Institutional Ethics 
Board (IRB) of Shenzhen Second People’s 
Hospital.  
 
Construction of plasmids  
 
Human miR-495-3p promoter was produced by 
PCR and cloned into the pGL3-basic-luciferase 
reporter plasmid (Promega, Madison, WI). In 
order to construct the pGL3-control luciferase 
vector, the full-length of the 3'-UTR of WIF1 was 
subcloned into pEGFP-C3. Te synthetic RNAi 
was cloned into the pSuper-retropuro plasmid 
(Oligoengine, WA) to block endogenous WIF1 
expression. miR-495-3p inhibitor and mimics 
were bought from RiboBio (Guangzhou, China). 
 
Cell culture and transfection 
 
CCD18Co, DIFI, HCT-8, SW620, Caco-2, 
SW480, and HCT-116 cell lines were obtained 
from American Type Culture Collection (ATCC, 
USA) and maintained in DMEM containing 10% 
fetal calf serum (Hyclone) in an incubator at 5 % 
CO2 and 37 oC. The cells were transient 
transfected by miR-495-3p inhibitor or mimics, 
and siRNA-WIF1 using lipofectamine 2000 




HCT-116 cells were planted in 96-well plate at 2 
× 103 cells/well and cultured. Then, miR-495-3p 
inhibitor or mimics were transfected in cells for 
24 h. Twenty hours later, 50 µg MTT (Sigma, 
MO) was added in each well. After 4 h, 100 µL 
DMSO was dropped i-n each well to dissolve the 
formazan and the optical density at 450 nm was 
measured on a microplate reader (Bio-tek, USA). 
 
Spheroid formation assay 
 
HCT-116 cells were planted at density of 500 
cells/well in six well ultra-low cluster plate and 
maintained in DMEM / F12 medium 
supplemented with B27 at 1:50 (Invitrogen), 
bovine serum albumin at 0.4 % (Sigma), EGF at 
20 ng/mL (BD Biosciences), and insulin at 4 
mg/mL (Sigma) for 2 weeks. The number of 
spherical, tight, and non-adherent masses with 
diameter > 50 µm of HCT-116 cell spheres was 
counted under an inverted microscope. Efficiency 
of sphere formation (S) was computed as in Eq 
1. 
 
S (%) = (C/L)100 ………………….. (1)  
 





Luciferase reporter plasmids and miRNAs were 
co-transfected into HCT-116 cells. After 2 days, 
the luciferase activity was tested upon a 
luciferase assay kit (Promega, Madison, WI). 




TOPglow/FOPglow TCF reporter kit (Millipore) 
was used for the detection of Wnt signaling 
pathway activity. HCT-116 cells were transfected 
with TOPglow and FOPglow according to the 




ChIP assay was done as previously described 
[12]. In brief, HCT-116 cells were cross-linked 
with 1 % formaldehyde for 10 minutes and then 
incubated with 125 mM glycine. After 
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centrifugation, the nuclei were separated and the 
precipitation was suspended by lysis buffer, then 
sonicated to obtain 200 to 600 bp DNA fragment. 
Using an antibody against β-catenin, 
immunoprecipitation was performed with protein 
G magnetic beads. In addition, IgG was treated 
as negative control. Real-time PCR was applied 




RNase-free water (Promega) dissolved RNA was 
used to analyze gene expression according to 
the real-time PCR standard method.  2-△△Ct 
method was used to calculate changes in gene 




After different treatments for an indicated time, 
cells were washed in cold PBS and lysed with 
loading buffer for 30–60 min on ice. The samples 
were loaded on SDS-PAGE, and then transferred 
to polyvinylidene fluoride (PVDF) membrane. 
Next, the membrane was blocked in 5% nonfat 
milk and probed with different primary antibodies. 
Then the membranes were incubated in horse 
radish peroxidase (HRP)-conjugated secondary 
antibodies at 24 oC for 60 min. Finally, enhanced 
chemiluminescence (Thermo Fisher Scientific, 




All data analyses were adopted on SPSS 
software 16.0. The data are depicted as mean ± 
standard deviation (SD). Two-tailed one-way 
ANOVA or two-tailed Student’s t-test was used 
for data comparison. Correlation between miR-
495-3p and WIF1 expressions in the specimens 
was analyzed by Spearman rank correlation test. 




MiR-495-3p increased in colon cancer cell 
lines and tissues 
 
To investigate miR-495-3p expression in human 
colon cancer, we searched TCGA database and 
compared miR-495-3p expression in 85 human 
colon cancer tissues and 33 normal colon 
tissues. Further, the content of miR-495-3p in 
colon cancer tissues was significantly 
upregulated compared with control (p < 0.05, 
Figure 1A). Moreover, it was found that miR-495-
3p levels were obviously increased compared 
with normal colon cell line CCD18Co in 6 colon 
cancer cell lines (p < 0.05, Figure 1B). Next, 10 
paired our hospital colon cancer and 
corresponding para-carcinoma tissues were 
detected by real-time PCR. It was observed that 
miR-495-3p level in colon cancer tissues was 
obviously increased compare to normal tissues, 
which indicated its elevation in colorectal cancer 
(p < 0.05, Figure 1C). 
 
MiR-495-3p facilitated proliferation and 
spheroid formation of HCT-116 cell 
 
As miR-495-3p was upregulated in colon cancer, 
miR-495-3p may involve in facilitating colon 
cancer proliferation. It was showed that 
expression of MiR-495-3p was changed by miR-
495-3p mimics as well as inhibitor transfection 
(Figure 2A, Figure 2B). Next, MTT assay 
demonstrated that miR-495-3p mimics elevated, 
whereas miR-495-3p inhibitor significantly 
declined HCT-116 cell viability after 96 h 
treatment (Figure 2C). As shown in Figure 2B 
compared with control group, miR-495-3p 
simulations significantly enhanced the spheres 
formation, whereas the miR-495-3p inhibitor 
reduced the number of spheres. It indicates that 
miR-495-3p may affect HCT-116 cell viability and 
spheroid formation. 
 
MiR-495-3p promoted Wnt signaling pathway 
 
Previous studies revealed that Wnt signaling 
pathway may be involved in colon cancer cell 
proliferation and stemness, thus we speculated 
that miR-495-3p may achieve its impact on colon 
cancer cells via Wnt signaling pathway. 
TOP/FOP ratio was considerably elevated in 
HCT-116 cells when miR-495-3p was 
upregulated, while it reduced in cells with miR-
495-3p-in transfection (p < 0.05, Figure 3A). We 
further assessed the influence of miR-495-3p on 
β-catenin nuclear translocation. After its 
extraction from the cytoplasm and the nucleus, 
the levels of various proteins were measured 
using western blotting. It was shown that content 
of β-catenin in the nucleus was markedly 
increased in the miR-495-3p group (p < 0.05, 
Figure 3B). Furthermore, real time PCR showed 
that various target genes were increased by miR-
495-3p and downregulated by inhibitor of miR-
495-3p (p < 0.05, Figure 3C). Moreover, ChIP 
assay was applied to evaluate the activity of Wnt 
signaling pathway. It was found that the 
upregulated miR-495-3p promoted nuclear β-
catenin binding with the promoter of MMP-9 and 
RUNX2, enhancing gene transcription and help 
colon cancer cell proliferation (p < 0.05, Figure 
3D). Furthermore, genes related with stemness 
were upregulated in HCT-116 cells with 
transfection of miR-495-3p, such as SOX-9, 
OCT-4, and Klf4, (p < 0.05, Figure 3E). 
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Figure 1: MiR-495-3p level increased in colon cancer cells and tissues. A = MiR-495-3p level in TCGA database; 
B = Expression of MiR-495-3p in colon cancer and normal colon cells; C; MiR-495-3p level in paired colon cancer 
and adjacent normal tissues; *p < 0.05 
 
 
Figure 2. MiR-495-3p promoted proliferation and spheroid formation of HCT-116 cell. A = MiR-495-3p level in 
HTC-116 cells after transfection of miR-495-3p simulations or inhibitor; B = Cell viability of HCT-116 with 
treatment of miR-495-3p mimics or transfection of inhibitor; C = Cell tumorigenesis ability of HCT-116 evaluated 
by spheroid formation assay after treatment with miR-495-3p simulations or inhibitor; *p < 0.05 
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Figure 3: MiR-495-3p promoted Wnt signaling pathway. A = Wnt signaling pathway activity was determinates by 
TOP/FOP ratio; B = Nuclear level of β-catenin was detected by western blotting; C = Expressions of cyclin D1, 
OCN, and ALP mRNA were detected by real-time PCR. D = MMP-9 and RUNX2 were detected by ChIP. E. Cell 
stemness related mRNA expressions were detected using real-time PCR, *p < 0.05 
 
MiR-495-3p targeting WIF1 during spheroid 
formation 
 
Upon checking the miRNA database, it was 
suggesting that miR-495-3p may bind with WIF1 
mRNA based on complementary pairing (Figure 
4A). After Luciferase assay, it was demonstrating 
that miR-495-3p dose-dependently reduced the 
luciferase intensity of WIF1 3’-UTR, while there 
was no significant impact on WIF1 3’-UTR 
mutation (Figure 4B, Figure 4C). In contrast, the 
knockdown WIF1 would enhance the spheroid 
formation of HCT-116 cells though decreasing 
miR-495-3p inhibitor (p < 0.05, Figure 4D). 
Concurrently, it was negatively correlated 
between WIF1 level and miR-495-3p, also 




Several studies have exhibited the influence of 
miRNAs in colon cancer tumorigenesis, including 
miR-145 [13], let-7 [14], miR-320b [15]. These 
observations focus attention on miRNA based 
treatment for colon cancer [16,17]. 
 
By searching TCGA database, we observed that 
miR-495-3p expression was enhanced in colon 
tumor specimens than in the control. A similar 
result was also observed in 6 colon cancer cell 
lines compared with CCD18Co. Therefore, we 
proposed that miR-495-3p may participate in 
human colon cancer oncogenesis. The influence 
of miR-495-3p upregulation and miR-495-3p 
inhibition were further assessed using MTT 
assay and spheroid formation assay. The result 
indicates that miR-495-3p overexpression 
increased growth and spheroid formation. On the 
contrary, miR-495-3p suppression results in 
weaker cell viability and spheroid formation. 
These results agreed with the opinion that miR-
495-3p regulates cell proliferation in colon cancer 
cells. 
 
The potential targets of miR-495-3p was further 
identified in miRanda databases to, which was 
further tested by luciferase assay. The results 
indicate that miR-495-3p directly obstructs WIF1 
mRNA translation into protein.  
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Figure 4: MiR-495-3p targeting WIF1 during spheroid formation, the cells were transfected with WIF1-3’ UTR-
mutation reporter together with miR-495-3p mimics or inhibitor. A = miR-495-3p targeting the 3’ UTR of WIF1; B. 
Dual-luciferase reporter assay of the WIF1-3’ UTR in HCT-116 cells; C = Dual-luciferase reporter assay detection 
of WIF1-3’ UTR-mutation in HCT-116 cells; D = Spheroid formation assay of HCT-116 cell for testing 
tumorigenesis ability after WIF1 knockdown together with miR-495-3p inhibitor transfection; E = Correlation 
analysis of miR-495-3p and WIF1 mRNA in colon cancer tissues; *p < 0.05 
 
To explore whether WIF1 regulates colon cancer 
cell tumorigenesis, we performed WIF1 
knockdown and studied spheroid formation in 
vitro. Cell spheroid formation decreased by miR-
495-3p inhibition was apparently enhanced by 
WIF1 downregulation. Furthermore, Pearson 
correlation analysis of miR-495-3p and WIF1 
expression in colon cancer patients exhibited a 
negative correlation. WIF1 is a lipid-binding 
protein that combines with Wnt protein to prevent 
the activation of Wnt/β-catenin pathway [18]. At 
present, WIF1 gene expression is dysregulated 
in the peripheral blood of human colon cancer 
and could be treated as a promising marker [19]. 
In accord with previous reports, we observed that 
WIF1 may participate in colon cancer cell viability 
and growth. 
 
Wnt/β-catenin signaling pathway plays a key role 
in promoting the progress of colon cancer [20] 
and is thought to be extremely important in 
tumorigenesis [21]. This pathway affects several 
biological behaviors, including proliferation, 
invasion, angiogenesis, migration, and apoptosis 
[22-24]. Abnormal expression of molecules within 
Wnt/β-catenin signaling is proposed to 
participate in the progress of colon cancer. 
Wnt/β-catenin signaling can be restrained by 
multiple factors through bindingto the Wnt ligand 
or receptors, including Frizzled related proteins 
(sFRPs), WIF1, and CTNNBIP1 [25]. Our results 
showed that WIF1 is suppressed by miR-495-3p 
in colon cancer cells and tissues, leading to Wnt 
signaling aberrant activation. Also, miR-495-3p 
overexpression facilitated the activation of 
stemness markers, such as SOX9, CD133, and 
Klf4. 
 
Since we found that WIF1 is regulated by miR-
495-3p and former studies reported that it affects 
Wnt/β-catenin signaling, we explored the impact 
of miR-495-3p on the ratio of TOP/FOP and β-
catenin nuclear translocation. We discovered that 
miR-495-3p upregulation accelerated β-catenin 
nuclear translocation and elevated TOP/FOP 
ratio, which further confirms the character of 
miR-495-3p in mediating Wnt/β-catenin signaling 
pathway. Multiple growth-promoting genes were 
activated by Wnt/β-catenin signaling at the 
transcription level, such as cyclin D1, OCN, ALP, 
MMP-9, and RUNX2 [26-29]. We observed that 
the levels of cyclin D1, OCN, and ALP were 
markedly enhanced by miR-495-3p mimics and 
inhibited by miR-495-3p inhibitor. Meanwhile, the 
combining capacity of β-catenin with the 
promoter of MMP-9 and RUNX2 was enhanced 
after miR-495-3p upregulation.  
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MiR-495-3p is elevated in colon cancer. This 
oncogene is a negative controller of Wnt/β-
catenin signaling inhibitor, and abnormal 
activation of miR-495-3p in colon cancer 
enhances Wnt/β-catenin signaling pathway. This 
aberrant signaling further facilitates cells to 
accelerate spheroid formation and stemness, 
leading to colon cell proliferation and 
tumorigenesis. The results in this study provide a 
new insight into colon cancer pathogenesis and a 
potential direction for colon cancer therapy, as 
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